Screenings beneficial in common tuberculosis areas
In areas of the UK where tuberculosis has a high prevalence, screenings could increase diagnosis both of active and latent forms of the disease and therefore could help prevent its spread.
These are the findings of a study, researchers from the Centre for Health Science, Queen Mary´s School of Medicine and Dentistry, London did on 50 general practices in Hackney, East London, UK to promote screening for tuberculosis in primary care. The practices were divided into two groups of 25: intervention and control.
The researchers found that detection rates for active tuberculosis in intervention practices were 13% higher than those in the control group, while detection rates for the latent form of the disease were also 10 % higher in the practices with the screening programme. The rates of BCG vaccination against tuberculosis were seven times higher for the practices implementing screening against the control group. All in all a seven-fold increase in BCG coverage in people aged five and over represents a striking improvement, since most interventions boost immunisation in primary care by five to 20 %.
Hackney was selected as it is one of the areas where tuberculosis is defined as common (more than 40 per 100,000 inhabitants are affected) due to high numbers of migrants from Africa and Eastern Europe, countries which have a spot of multi-drug resistant tuberculosis.
The conclusion of the authors is, that screening could have a clinically important effect, and could be recommended as part of tuberculosis control initiatives in industrialised countries.
A new study proposes a new antiviral strategy against SARS-CoV-2 based on a treatment that combines two complementary approaches, capable of attacking the virus simultaneously.
Article • Avoiding mistakes in design, equipment, validation, and operation
Microbiological cleanliness in laboratories demands far more than routine disinfection – it requires a comprehensive contamination control strategy from the very first design stage. At the Labs…
Why does the same genetic mutation cause FCDII in some patients but not in others? Researchers developed organoids to model a brain malformation responsible for drug-resistant epilepsy in children.
This website uses cookies to give our readers the best website experience. Please refer to our privacy policy to find out how we use cookies and how you can edit your preferences.